Search Results for "Sunitinib"

12:50 EST 21st November 2014 | BioPortfolio

Matching Channels


Matching News

Sunitinib: First Drug Active in Refractory Meningioma

In refractory atypical/malignant meningioma, sunitinib is associated with good progression-free survival, but also with high toxicity rates. Medscape Medical News

Sunitinib or Everolimus First-Line for Kidney Cancer?

A phase 2 randomized comparator trial has found that first-line everolimus is not as effective as first-line sunitinib, and has a different toxicity profile. Medscape Medical News

Sunitinib malate (Sutent) for renal cell carcinoma – adjuvant therapy

Sunitinib malate (Sutent) is an oral small-molecule inhibitor with selectivity for platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1,...

[News] Sunitinib still first-line therapy for metastatic renal cancer

Everolimus (an mTOR inhibitor) does not yield better results compared with sunitinib (a VEGFR tyrosine kinase inhibitor) as first-line therapy in patients with metastatic renal-cell carcinoma, new res...

Older patients benefit from lower doses of sunitinib in renal cell carcinoma

"We must dispel this concept of ageism," Dr Kanesvaran tells ecancertv at SIOG 2014. He discusses his study on sunitinib in metastatic renal cell carcinoma, which found that patients benefit from a...

Pfizer Wins SUTENT® Patent Case

Pfizer announced that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT® (sunitinib malate) capsules. This decision, which is s...

Pfizer Wins Patent Case in Delaware District Court

Pfizer Inc. announced that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering Sutent (sunitinib malate) capsules. This decision, which i...

Kidney cancer: Lenalidomide plus sunitinib hampered by toxicity

Matching PubMed Articles

Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma.

Sunitinib is a multiple tyrosine kinase receptor inhibitor that is approved for the treatment of metastatic renal cell carcinoma (RCC). However, neither an appropriate dose nor dosing schedule of suni...

A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma.

Sunitinib has become a standard treatment agent for metastatic renal cell carcinoma (RCC) for several years. However, various adverse events have been reported. We present a rare adverse effect of hyp...

Contribution of Plasma Proteins, Albumin and Alpha 1-Acid Glycoprotein, to Pharmacokinetics of a Multi-targeted Receptor Tyrosine Kinase Inhibitor, Sunitinib, in Analbuminemic Rats.

The present study investigated the role of the major plasma proteins, albumin and α1-acid glycoprotein (AAG), in the pharmacokinetics of sunitinib using Sprague-Dawley (SD) rats and analbuminemic rat...

Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.

Sunitinib is an oral multitargeted tyrosine kinase inhibitor used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse effects (RAEs) of sunitinib have not been investigated....

Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

Previously published pharmacokinetics (PK) models for sunitinib and its active metabolite SU12662 were based on a limited dataset or lacked important elements such us correlations between sunitinib an...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement